(due) drug use evaluation
TRANSCRIPT
![Page 1: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/1.jpg)
Norah Al JohanyHead of Pharmacoeconomic department General administration of pharmaceutical [email protected]
Drug
Use Evaluation (DUE)
“Utilization”
![Page 2: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/2.jpg)
![Page 3: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/3.jpg)
Estimate cost of drug-related
morbidity and mortality
![Page 4: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/4.jpg)
Clinical Pharmacists Affect Mortality
Seven services associated with reduced mortality rate:
1. Drug Use evaluation
2. Patient Education
3. ADR Management
4. Pharmacy Protocol Management
5. Code Team Participation
6. Admission Drug Histories
7. Participation on Rounds
Pharmacotherapy 2007;27(4):481-493
![Page 5: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/5.jpg)
Definition
DUE is a performance improvement method that focuses on evaluating and improving medication –use processes with the goal
of optimal patient outcomes
Am J Hosp Pharm. 1996;53:1953-5
![Page 6: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/6.jpg)
Medication Use Evaluation (MUE), or
Drug Use Evaluation (DUE)
Patient outcomes
Evaluating medication
use
Systematically
Monitoring
Program
![Page 7: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/7.jpg)
Medication Use Evaluation (MUE)
Drug Use Evaluation (DUE)OR
Patient out comes &
IndividualPatient quality
of life
![Page 8: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/8.jpg)
Inventory management
Prescribing
Preparing
Dispensing
Administration
Monitoring
Patient out comes
Formulary management
Identify Resolve Prevent
medication related problems
(MUE) process helps to
![Page 9: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/9.jpg)
MUE Objectives
• Promoting optimal medication therapy.
• Preventing medication-related problems.
• Evaluating the effectiveness of medication therapy.
• Improving patient safety.
• Stimulating improvements in medication-use processes.
• Stimulating standardization in medication-use processes
![Page 10: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/10.jpg)
MUE Objectives
• Enhancing opportunities, through standardization, to assess the value of innovative medication-use practices from both patient-outcome and resource-utilization perspectives.
• Minimizing procedural variations that contribute to suboptimal outcomes of medication use
• Identifying areas in which further information and education for health care professionals may be needed.
![Page 11: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/11.jpg)
• Minimizing costs of medication therapy. These costs may be only partly related to the direct cost of medications themselves. When medications are selected and managed optimally from the outset, the costs of complications and wasted resources are minimized, and overall costs are decreased
• Meeting or exceeding internal and external quality standards
(e.g., professional practice standards, accreditation standards, or government laws and regulations)
MUE Objectives
![Page 12: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/12.jpg)
Types Of MUE
• Specific medication (e.g. alteplase)
• Class of medication (e.g., thrombolytics)
• Medications used in the management of a specific disease state or clinical setting (e.g. thrombolytics in acute myocardial infarction)
![Page 13: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/13.jpg)
Types Of MUE
• Medications related to clinical event (e.g., drug therapy with in the first 24 hours for patients admitted with acute MI)
• Specific component of the medication use process (e,g time from admission to administration of thrombolytics
• Based on a specific outcome (vessel patency following thrombolytic administration)
![Page 14: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/14.jpg)
Steps of the MUE Process
• Establish organizational authority for the MUE process and identify responsible individuals and groups.
• Develop screening mechanisms (indicators) for comprehensive surveillance of the medication-use system.
• Set priorities for in-depth analysis of important aspects of medication use.
• Inform health care professionals (and others as necessary)
in the practice setting(s) about the objectives and expected benefits of the MUE process.
• Establish criteria, guidelines, treatment protocols, and standards of care for specific medications and medication-use processes. These should be based on sound scientific evidence from the medical and pharmaceutical literature
![Page 15: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/15.jpg)
Steps of the MUE Process
• Educate health care professionals to promote the use of criteria, guidelines, treatment protocols, and standards of care.
• Establish mechanisms for timely communication among health care professionals.
• Initiate the use of MUE criteria, guidelines, treatment protocols, and standards of care in the medication-use process.
• Collect data and evaluate care.
• Develop and implement plans for improvement of the medication-use process based on MUE findings (if indicated)
![Page 16: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/16.jpg)
• Assess the effectiveness of actions taken, and document improvements
• Incorporate improvements into criteria, guidelines, treatment protocols, and standards of care, when indicated.
• Repeat the cycle of planning, evaluating, and taking action for ongoing improvement in medication-use processes.
• Regularly assess the effectiveness of the MUE process itself and make needed improvements.
Steps of the MUE Process
![Page 17: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/17.jpg)
Indicators Suggesting a Need for
MUE Analysis
• Preventable adverse drug reactions, and toxicity
• Medication errors
• The medication is most effective when used in a specific way.
• Signs of treatment failures
• Pharmacist interventions to improve medication therapy
• Formulary management
• Patient dissatisfaction or deterioration in quality of life.
• Expensive medication
• frequently prescribed.
![Page 18: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/18.jpg)
Roles and Responsibilities
in the MUE Process
• Quality management committee
• Pharmacy and therapeutics committee
should have, at a minimum, prescriber, pharmacist, nurse, and administrator representation.
• Temporary working groups may be used for.
![Page 19: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/19.jpg)
Pharmacist’s Responsibilities in
MUE
• Plan
• Management
• goals
• Collaboration
• Education
• Reviewing individual medication orders
• Data collection
• Reporting
![Page 20: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/20.jpg)
Resources
• The primary
• Published criteria, such as found in AJHP and ASHP’s Criteria for Drug Use Evaluation (volumes 1–4), provide.
• Computer software programs
• External standards-setting bodies, such as the Joint Commission on Accreditation of Healthcare Organizations,
![Page 21: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/21.jpg)
Criteria
• Are statements of the activity to be measured
• Should be based on the best practice
• Appropriate for the target patient population
• Supported by current literature
• Multidisciplinary group develops the criteria
• Should be phrased yes/no or T/F
• Should avoid interpretation on the part of data collection
• Assess important aspects in the use of the medication evaluated
• Focus on aspects related to outcomes.
![Page 22: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/22.jpg)
![Page 23: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/23.jpg)
![Page 24: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/24.jpg)
![Page 25: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/25.jpg)
![Page 26: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/26.jpg)
![Page 27: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/27.jpg)
The Report
• Should contain the rationale for the topic selection
• Team members involved in the evaluation
• Description of the patient population evaluated
• Any selection criteria used
• A copy of the criteria /indicators
• Discussion of the results
• Identification of likely causes for opportunities identified
• Recommendations for corrective action
• Follow –up evaluation
![Page 28: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/28.jpg)
Follow up
• The same criteria, standards, and sample should be used for the follow up assessment as in the initial assessment
![Page 29: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/29.jpg)
Pitfalls
• Lack of authority
• Lack of organization
• Poor communication
• Poor documentation
• Lack of involvement
• Lack of follow-through
• Lack of readily retrievable data and information management
![Page 30: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/30.jpg)
Pitfalls
• Lack of authority.
• Lack of organization.
• Poor communication.
• Poor documentation.
• Lack of involvement.
• Lack of follow-through
• Evaluation methodology that impedes patient care
• Lack of readily retrievable data and information
![Page 31: (DUE) Drug use evaluation](https://reader034.vdocuments.mx/reader034/viewer/2022042817/55a74d141a28abc1638b457a/html5/thumbnails/31.jpg)